U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
180.21+0.89 (+0.50%)
At close: 4:00PM EDT

180.21 0.00 (0.00%)
After hours: 5:48PM EDT

People also watch
Full screen
Previous Close179.32
Bid179.01 x 100
Ask180.15 x 100
Day's Range179.16 - 180.55
52 Week Range133.64 - 184.21
Avg. Volume3,400,004
Market Cap132.53B
PE Ratio (TTM)17.12
Earnings DateN/A
Dividend & Yield4.60 (2.57%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com2 hours ago

    FDA Accepts Amgen's Biologics License Application for Aimovig

    The target action date is in May 2018

  • Barrons.com4 hours ago

    Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter?

    Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.

  • Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
    Zacks9 hours ago

    Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

    While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.